Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 3
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Oliver Illini, Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Tanja Čufer, Katja Mohorčič, Maximilian J Hochmair
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;capmatinib;tarčna terapija;real-world data;targeted therapy;
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population i ...
Leto: 2022 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
Oliver Illini, Maximilian J Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Katja Mohorčič
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;selperactinib;tarčna terapija;zaviralci tirozinskih kinaz;real-world data;selpercatinib;targeted therapy;tyrosine kinase inhibitor;
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Metho ...
Leto: 2021 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON)
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Urška Janžič, Katja Mohorčič, Marija Ivanović, Sayed M. S. Hashemi
Izvirni znanstveni članek
Oznake: medicina;non-small cell lung cancer;EGFR exon 20 inhibitors;mobocertinib;real-world data;exon 20 insertion;
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy ana ...
Leto: 2024 Vir: Repozitorij Univerze v Ljubljani (RUL)
Št. zadetkov: 3
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: